283 related articles for article (PubMed ID: 18765548)
21. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Lyman GH; Cosler LE; Kuderer NM; Hornberger J
Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
[TBL] [Abstract][Full Text] [Related]
22. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
23. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
24. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
26. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M; Lehnert M; Huynh A; Jakesz R; Singer C; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Grill R; Stierer M; Gnant MF; Filipits M;
Clin Cancer Res; 2008 Mar; 14(6):1767-74. PubMed ID: 18347178
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
28. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
[TBL] [Abstract][Full Text] [Related]
29. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen.
Murphy LC; Niu Y; Snell L; Watson P
Clin Cancer Res; 2004 Sep; 10(17):5902-6. PubMed ID: 15355923
[TBL] [Abstract][Full Text] [Related]
30. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
31. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
32. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Kawaguchi M; Miura Y; Iwase H
Clin Cancer Res; 2005 Jan; 11(1):193-8. PubMed ID: 15671546
[TBL] [Abstract][Full Text] [Related]
33. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.
Paik S
Oncologist; 2007 Jun; 12(6):631-5. PubMed ID: 17602054
[TBL] [Abstract][Full Text] [Related]
34. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
35. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
[TBL] [Abstract][Full Text] [Related]
36. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma.
Manders P; Beex LV; Tjan-Heijnen VC; Span PN; Sweep CG
Cancer; 2003 Nov; 98(10):2125-32. PubMed ID: 14601081
[TBL] [Abstract][Full Text] [Related]
38. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
[TBL] [Abstract][Full Text] [Related]
39. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Ma XJ; Hilsenbeck SG; Wang W; Ding L; Sgroi DC; Bender RA; Osborne CK; Allred DC; Erlander MG
J Clin Oncol; 2006 Oct; 24(28):4611-9. PubMed ID: 17008703
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy.
Rahko E; Jukkola A; Melkko J; Paavo P; Bloigu R; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
Anticancer Res; 2004; 24(6):4247-53. PubMed ID: 15736480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
